{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["42(6)"],"submitter":["Deng L"],"funding":["BeiGene"],"pubmed_abstract":["<h4>Introduction</h4>Our previous study has suggested a favorable progression-free survival (PFS) with zanubrutinib over orelabrutinib in patients with relapsed or refractory mantle cell lymphoma (R/R MCL). Here, we conducted an updated analysis to indirectly compare the long-term efficacy between zanubrutinib and orelabrutinib in patients with R/R MCL.<h4>Methods</h4>Individual patient data from the zanubrutinib study were adjusted to match the patient population profile of the orelabrutinib study. An unanchored matching-adjusted indirect comparison (MAIC) was performed to adjust for effect modifiers and prognostic variables. The efficacy outcomes included investigator-assessed PFS, overall survival (OS), and overall response rate (ORR). Response evaluations were only computed tomography "],"journal":["Advances in therapy"],"pagination":["2937-2949"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12085368"],"repository":["biostudies-literature"],"pubmed_title":["Indirect Comparisons of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with R/R MCL: An Extended Follow-up Analysis."],"pmcid":["PMC12085368"],"pubmed_authors":["Yang H","Li D","Zhang H","Deng L","Ji J","Fang C","Zou D","Lv F","Zhu J","Hu J","Xu S","Feng R","Xu W","Jin J","Zhou K","Gao S","Song Y"],"additional_accession":[]},"is_claimable":false,"name":"Indirect Comparisons of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with R/R MCL: An Extended Follow-up Analysis.","description":"<h4>Introduction</h4>Our previous study has suggested a favorable progression-free survival (PFS) with zanubrutinib over orelabrutinib in patients with relapsed or refractory mantle cell lymphoma (R/R MCL). Here, we conducted an updated analysis to indirectly compare the long-term efficacy between zanubrutinib and orelabrutinib in patients with R/R MCL.<h4>Methods</h4>Individual patient data from the zanubrutinib study were adjusted to match the patient population profile of the orelabrutinib study. An unanchored matching-adjusted indirect comparison (MAIC) was performed to adjust for effect modifiers and prognostic variables. The efficacy outcomes included investigator-assessed PFS, overall survival (OS), and overall response rate (ORR). Response evaluations were only computed tomography ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jun","modification":"2026-06-01T19:12:23.347Z","creation":"2026-05-19T03:07:20.455Z"},"accession":"S-EPMC12085368","cross_references":{"pubmed":["40317419"],"doi":["10.1007/s12325-025-03202-x"]}}